194 related articles for article (PubMed ID: 27751763)
1. Con: The Hepcon HMS Should Not Be Used Instead of Traditional Activated Clotting Time to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass.
Gilly G; Trusheim J
J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1730-1732. PubMed ID: 27751763
[No Abstract] [Full Text] [Related]
2. Pro: The Hepcon HMS Should Be Used Instead of Traditional Activated Clotting Time (ACT) to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass.
Ural K; Owen C
J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1727-1729. PubMed ID: 27641953
[No Abstract] [Full Text] [Related]
3. Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab.
Isaacs J; Welsby IJ; Schroder JN; Onwuemene OA
J Cardiothorac Vasc Anesth; 2021 Nov; 35(11):3299-3302. PubMed ID: 32928650
[TBL] [Abstract][Full Text] [Related]
4. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
[TBL] [Abstract][Full Text] [Related]
5. Real time measurement of heparin concentration during cardiopulmonary bypass.
Hashimoto K; Sasaki T; Hachiya T; Takakura H; Onoguchi K; Nagahori R; Takeuchi S
J Cardiovasc Surg (Torino); 1999 Oct; 40(5):645-51. PubMed ID: 10596996
[TBL] [Abstract][Full Text] [Related]
6. [Heparin monitoring during cardiopulmonary bypass in congenital heart surgery].
Isomatsu Y; Imai Y; Seo K; Terada M; Aoki M; Shin'oka T
Kyobu Geka; 2000 Nov; 53(12):1001-4. PubMed ID: 11079303
[TBL] [Abstract][Full Text] [Related]
7. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
[TBL] [Abstract][Full Text] [Related]
8. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
[TBL] [Abstract][Full Text] [Related]
9. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
[TBL] [Abstract][Full Text] [Related]
10. [A clinical evaluation of the Hepcon/HMS: a new device of monitoring hemostasis management during cardiopulmonary bypass].
Yamanishi H; Watanabe S; Hayashi K; Tomioka H; Minami M; Nozaki Y; Aoki T; Kawai Y; Kishino K; Ohta S
Kyobu Geka; 1997 Jun; 50(6):459-62. PubMed ID: 9185440
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of heparin concentration and activated clotting time monitoring (HEPCON HMS) system].
Sakurada T; Kikuchi Y; Koushima R; Nakashima S; Hachiro Y; Kagaya H
Nihon Kyobu Geka Gakkai Zasshi; 1997 Jun; 45(6):836-40. PubMed ID: 9217380
[TBL] [Abstract][Full Text] [Related]
12. Con: Activated Clotting Time Should Not Be Monitored During Heparinization for Vascular Surgery.
Wolo E; Herman C
J Cardiothorac Vasc Anesth; 2018 Jun; 32(3):1497-1499. PubMed ID: 29336967
[No Abstract] [Full Text] [Related]
13. Management of postoperative heparin rebound following cardiopulmonary bypass.
Pifarré R; Babka R; Sullivan HJ; Montoya A; Bakhos M; El-Etr A
J Thorac Cardiovasc Surg; 1981 Mar; 81(3):378-81. PubMed ID: 7464201
[TBL] [Abstract][Full Text] [Related]
14. Impact of protamine dose on activated clotting time and thromboelastography in infants and small children undergoing cardiopulmonary bypass.
Gautam NK; Schmitz ML; Harrison D; Zabala LM; Killebrew P; Belcher RH; Prodhan P; McKamie W; Norvell DC
Paediatr Anaesth; 2013 Mar; 23(3):233-41. PubMed ID: 23279140
[TBL] [Abstract][Full Text] [Related]
15. A Blinded Randomized Trial Comparing Standard Activated Clotting Time Heparin Management to High Target Active Clotting Time and Individualized Hepcon HMS Heparin Management in Cardiopulmonary Bypass Cardiac Surgical Patients.
Nuttall GA; Smith MM; Smith BB; Christensen JM; Santrach PJ; Schaff HV
Ann Thorac Cardiovasc Surg; 2022 Jun; 28(3):204-213. PubMed ID: 34937821
[TBL] [Abstract][Full Text] [Related]
16. A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass.
Chavez JJ; Foley DE; Snider CC; Howell JC; Cohen E; Muenchen RA; Carroll RC
Anesth Analg; 2004 Nov; 99(5):1290-1294. PubMed ID: 15502019
[TBL] [Abstract][Full Text] [Related]
17. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
[TBL] [Abstract][Full Text] [Related]
18. Less is more: We are administering too much protamine in cardiac surgery.
De Simone F; Nardelli P; Licheri M; Frau G; Redaelli MB; Monaco F; Zangrillo A; Landoni G
Ann Card Anaesth; 2021; 24(2):178-182. PubMed ID: 33884973
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
[TBL] [Abstract][Full Text] [Related]
20. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
